Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed that it bought back 152,500 H-shares on 9 September 2026 via on-market transactions on the Hong Kong Stock Exchange.

• Transaction details – Purchase price range: HK$17.16–HK$17.26 per share, implying an average cost of roughly HK$17.24. – Aggregate consideration: HK$2.63 million.

• Capital structure impact – Outstanding H-shares (excluding treasury) fell 0.03% to 540.20 million from 540.35 million. – Treasury shares rose to 11.74 million, keeping total issued shares steady at 551.94 million. – No repurchased shares have been cancelled; all are held as treasury stock.

• Mandate utilisation – The repurchase forms part of the mandate approved on 16 June 2026 authorising buybacks of up to 54.10 million shares. – Cumulative repurchases under the mandate now total 774,000 shares, representing 0.14% of the company’s issued shares at the mandate date.

• Post-repurchase restriction – In line with Hong Kong listing rules, Fosun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 9 October 2026.

The company confirmed that the transactions complied with the Hong Kong Stock Exchange Main Board Rules and that no material changes have been made to the explanatory statement outlined in its circular dated 11 May 2026.